Skip To Main Content
Sunil Parimi on Muck Rack

Sunil Parimi

As seen in: Nature, Canadian Urological Association Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Sunil Parimi’s profile

Articles by Sunil Parimi

Genetic testing practices among specialist physicians who treat prostate cancer

|
By Tamim Niazi, Steven M. Yip, Robert Hamilton, Michael Kolinsky, Geoffrey Gotto, Sebastien J Hotte, Michael Ong, Ricardo Rendon, Cristiano Ferrario, Fred Saad, Kim N. Chi, Jenny J. Ko, Sunil Parimi, Bobby Shayegan, Shawn Malone, Elie Antebi
| Canadian Urological Association Journal Verified
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association.
Open in Who Shared View Duplicates (6) Issue with article?

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer - Nature Communications

|
By David Muller, David Müller, Andrew Murtha, Jack Bacon, Maria Stephenson, Connor Wells Verified, Carlos Vasquez-Rios, Kimia Rostin, Lisa Rebane, Jussi Nikkola, Nimira Alimohamed, Naveen S. Basappa, Daygen L. Finch, Jenny J. Ko, Jean-Michel Lavoie, Lucia Nappi, Krista Noonan, Michael Ong, Guliz Ozgun, Sunil Parimi, Maryam Soleimani, Srikala S. Sridhar, Paul Toren, Eric Winquist, Cecily Q. Bernales, Emily Fung, Laiba Khan, Dalia Othman, Tarek A. Bismar, Gang Wang, Andreas Papadakis, Alan Spatz, Christian Kollmannsberger, Matti Annala, Kim N. Chi, Gillian Vandekerkhove, Bernhard J. Eigl, Elena Schönlau, Melissa Koudjanian, Jaskirat Atwal, Bryndan Eigl, Reem Merza, Corinne Maurice-Dror
| Nature Verified
Abstract Fibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity. Plasma circulating tumor DNA (ctDNA) offers a complementary testing strategy, but the added value of ctDNA relative to conventional FGFR alteration assessment remains unclear.
Open in Who Shared Issue with article?

Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer

|
By Sunil Parimi, BC Cancer, Erica Tsang, Suraya Bondy
| Canadian Urological Association Journal Verified
Sunil Parimi BC Cancer Suraya Bondy Erica Tsang Michael Ross McKenzie Francois Bachand Maria Aparicio Graeme Duncan Katherine Sunderland Robert Anton Olson Howard Huaihan Pai Abraham Skaria Alexander Vincent LaPointe Kim Nguyen Chi Scott Tyldesley Keywords: Radium-223, pain response, metastatic castration resistant prostate cancer Abstract Introduction: Clinical trials have shown that radium-223 (Ra223) can prolong survival and improve quality of life in patients with metastatic...
Open in Who Shared Issue with article?

A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion

|
By Michael McKenzie, Sunil Parimi, Erica Tsang, Abraham Alexander
| Canadian Urological Association Journal Verified
Introduction: Radium 223 (Ra223) given for six cycles has proven efficacy in clinical trials, but its population-level generalizability has not been well-described. The objectives of this study were to describe population-based Ra223 use in the abiraterone and enzalutamide era and identify factors associated with completion. Methods: All Ra223 patients at the British Columbia Cancer Agency between September 2013 and February 2016 were identified.
Open in Who Shared Issue with article?
Show More